Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elici...

Descripción completa

Detalles Bibliográficos
Autores principales: Madan, Ravi A, Heery, Christopher R, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323/
https://www.ncbi.nlm.nih.gov/pubmed/25097802
http://dx.doi.org/10.4161/onci.28611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323/
https://www.ncbi.nlm.nih.gov/pubmed/25097802
http://dx.doi.org/10.4161/onci.28611

Ejemplares similares